About Canntab Therapeutics Ltd
Sector
CEO
Richard Goldstein
Headquarters
Markham
Website
Founded
2010
ISIN
CA1377991023
FIGI
BBG0072K1NK3
Canntab Therapeutics Ltd. is a biopharmaceutical company. It engages in the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm's products include nanoemulsion technology, multi-particulate drug delivery systems, specialty gel capsules, propriety granulation technology, oral quick dissolve tablet, instant release solid oral, extended release solid oral, and bi-layer solid oral. The company was founded by Richard Goldstein and Jeffrey W. Renwick on May 31, 2010 and is headquartered in Markham, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CTABF is 0.0073 USD — it has increased by 356.25% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Canntab Therapeutics Ltd stocks are traded under the ticker CTABF.
CTABF stock is 78.08% volatile and has beta coefficient of 3.35. Check out the list of the most volatile stocks — is Canntab Therapeutics Ltd there?
Yes, you can track Canntab Therapeutics Ltd financials in yearly and quarterly reports right on TradingView.
No, CTABF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTABF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Canntab Therapeutics Ltd stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Canntab Therapeutics Ltd technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Canntab Therapeutics Ltd stock shows the sell signal. See more of Canntab Therapeutics Ltd technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.